Clop02-a (Clop02 A)
Clopidogrel Tablet
Product Images NDC 50090-7466
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50090-7466). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Clop03-a (Clop03 A)
This data shows the cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke over a period of 12 months of follow-up for patients who were given either placebo or clopidogrel in addition to aspirin. The numbers indicate a significant difference in event rates between the two groups, with clopidogrel showing a lower rate. Other standard therapies were also utilized in both groups.*
Clop04-a (Clop04 A)
This document appears to be a medical chart or data table showing information related to the usage and effectiveness of various medications in a medical study or trial. It includes details regarding the history of heart-related incidents (MI, stroke), the administration of different medications (Heparin/LMWH, Aspirin, GPIIb/IIIa Antag, Beta-Blocker, Ace Inhibitor), and the outcomes in terms of the number and percentage of patients receiving Clopidogrel and Placebo. Additionally, there seems to be a comparison of outcomes favoring Clopidogrel versus Placebo and a hazard ratio analysis. *
Clop08-a (Clop08 A)
This is a comparison of the cumulative event rate (%) of fatal or non-fatal vascular events between aspirin and clopidogrel over a period of 30 months of follow-up. The statistical significance of the results is indicated with p=0.045.*
Clop_01 (Clop 01)
Clop_05 (Clop 05)
This information compares the rate of death between patients who received a placebo and those who took Clopidogrel tablets. The data shows that there was a 7% proportional risk reduction in deaths in the group that took Clopidogrel tablets compared to the placebo group. The results are statistically significant with a p-value of 0.03. All treated patients in the study received aspirin.*
Clop_06 (Clop 06)
This text provides information on the comparison between Placebo and Clopidogrel Tablets in terms of the occurrence of events such as death, reinfarction, or stroke before discharge. It indicates a 9% proportional risk reduction with Clopidogrel Tablets compared to Placebo. The data represents patient outcomes over 28 days since randomization. All patients in the study received aspirin treatment.*
Clop_07 (Clop 07)
This data appears to be a table showing statistics related to a study or research on a particular treatment or intervention. It includes information on subgroups based on gender, age, time since onset, blood pressure, heart rate, and the administration of fibrinolytic agents. Additionally, there are results related to the administration of Clopidogrel tablets and placebo in different scenarios. Odds ratios and confidence intervals may also be mentioned for certain comparisons.*
Clop_09 (Clop 09)
Label Image (Lbl500907466)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
